
- /
- Supported exchanges
- / F
- / 7PO.F
Poxel S.A (7PO F) stock market data APIs
Poxel S.A Financial Data Overview
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Poxel S.A data using free add-ons & libraries
Get Poxel S.A Fundamental Data
Poxel S.A Fundamental data includes:
- Net Revenue: 1 981 K
- EBITDA: -11 989 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Poxel S.A News

Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
LYON, France, July 18, 2023--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serio...


Poxel, winner of the 2023 edition of the I-nov contest
This program rewards companies innovating on strategic themes for French sovereignty Additional evidence of the technological value of Poxel's assets LYON, France, July 05, 2023--(BUSINESS WIRE)--Reg...

Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris
LYON, France, June 30, 2023--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic ser...

Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting
Shareholders approved all proposed resolutions by the Board of Directors LYON, France, June 23, 2023--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a cli...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.